• TechCrunch
• CrunchBase
• More
  • TechCrunch Europe
  • TechCrunch France
  • TechCrunch Japan

Gemin X Pharmaceuticals

edit

Gemin X Pharmaceuticals is dedicated to the discovery, development and commercialization of novel, targeted cancer therapeutics to improve the lives of patients.

Gemin X’s research on the Bcl-2 cell death regulation pathway has led to the discovery of GX15-070 (obatoclax), a novel small molecule that selectively reinitiates programmed cell death, or apoptosis, and may also be effective in inducing cancer cell self-digestion, or autophagy. Obatoclax has shown promising activity in both preclinical and early human clinical studies and is currently in Phase 2 clinical trials as both a single agent and combination therapy. Obatoclax has patent protection through 2025.

Recent Milestones

edit

• 
  Gemin X Pharmaceuticals was acquired by Cephalon for $525M. (3/21/11)
  Posted 3/21/11 at 6:36pm via cephalon.com
• 
  Gemin X Pharmaceuticals received $8M in Series E funding. (8/24/10)
  Posted 8/24/10 at 3:28am via onbiovc.com
• 
  Gemin X Pharmaceuticals received $16M in Series D funding. (4/20/10)
  Posted 4/20/10 at 12:20pm via fiercebiotech.com
• 
  Gemin X Pharmaceuticals received $38M in Series C funding. (7/3/08)
  Posted 3/11/10 at 1:31am via siliconindia.com
• 
  Gemin X Pharmaceuticals added Peter R. Dolan as Chairman and Chief Executive Officer.
  Posted 3/21/11 at 11:45pm
• 
  Gemin X Pharmaceuticals added Gordon C. Shore as Chief Scientific Officer and Co-founder.
  Posted 3/21/11 at 11:45pm
• 
  Gemin X Pharmaceuticals added Michael Dixon as Chief Financial Officer.
  Posted 3/21/11 at 11:45pm
• 
  Gemin X Pharmaceuticals added Jean Viallet as Executive Vice President and Chief Medical Officer.
  Posted 3/21/11 at 11:45pm

Videos

Screenshots

edit

Above: Gemin X Pharmaceuticals
Uploaded: 3/11/10

Sources

1. Cephalon Announces Definitive Agreement to Acquire Gemin X (cephalon.com) [edit]
2. Gemin X Pharmaceuticals closes $38 Mn Series C financing (siliconindia.com) [edit]
3. Gemin X books $16M Series D as it pursues PhIIb cancer trial Read more: http://www.fiercebiotech.com/story/gemin-x-books-16m-series-d-it-pursues-phiib-cancer-trial/2010-04-20#ixzz0lfnwA8xR (fiercebiotech.com) [edit]
4. Gemin X Pharmaceuticals, Inc.: Series E $8M (onbiovc.com) [edit]